|
|||
2011-03-17 15:00:00 CET 2011-03-17 15:00:25 CET REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsNotification according to Chapter 2, Section 10 of the Finnish Securities Market ActBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 17 March 2011 at 4.00 p.m. Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a notification regarding changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act, described below. The notification received by the Company concerns the changes in holdings of Versant Ventures III LLC (through Versant Venture Capital III LP and Versant Side Fund III LP). The mentioned change in holdings is related to the private placement of shares (the "Offering") described in more detail in a stock exchange release issued on 11.3.2011. In the Offering a total of 35,230,000 newly issued and 14,747,084 treasury shares were offered to Finnish and international institutional and strategic investors. According to the notification received by the Company, the resulting holdings of shares and votes in the Company of Versant Ventures III LLC (through Versant Side Fund III LP and Versant Venture Capital III LP) after the conveyance of treasury shares and registration with the Finnish Trade Register of the new shares issued will be as follows: Name Number of Number of Number of Share of Share of shares before voting rights shares and share voting the Offering before the voting rights capital rights Offering after the after the after the Offering Offering Offering (%) (%) Versant Side 201,237 201,237 201,237 0.05 0.05 Fund III LP (controlled by Versant Ventures III LLC) Versant 34,067,104 34,067,104 34,067,104 8.79 9.14 Venture Capital III LP (controlled by Versant Ventures III LLC) Versant 34,268,341 34,268,341 34,268,341 8.84 9.19 Ventures III LLC (through Versant Side Fund III LP and Versant Venture Capital III LP) in total The number of voting rights and percentages presented above are calculated based on number of shares and voting rights after the conveyance of the treasury shares and registration of the new shares with the Finnish Trade Register taking into account the treasury shares held by the Company or its group companies after the conveyance of the treasury shares and registration of the new shares. On the date hereof, the registered number of shares in Biotie is 352,364,457. Of these shares 29,659,239 are held by the Company or its group companies and the number of outstanding shares and voting rights attached to the shares thus amounts to 322,705,218. Subsequent to the registration of the new shares issued in the Offering, the aggregate number of Biotie shares will be 387,594,457. Of these shares, 14,912,155 will be held by the Company or its group companies. Turku, 17 March 2011 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail:virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1497771] |
|||
|